Polpharma Biologics Partners with MS Pharma to Boost Biosimilar Access in MENA

Polpharma Biologics has signed licensing agreements with MS Pharma to commercialize three biosimilars, vedolizumab, ocrelizumab, and guselkumab, across the Middle East and North Africa. MS Pharma will handle registration, marketing, distribution, and local fill-and-finish operations, while Polpharma will continue to develop, manufacture, and supply.

 

Industry Impact

The partnership strengthens the availability of biologic treatments for ulcerative colitis, multiple sclerosis, and plaque psoriasis, enhancing patient access in the MENA region. It also reflects a broader trend of localizing biologics production to support healthcare sustainability.

 

Key Takeaway

By combining Polpharma’s manufacturing expertise with MS Pharma’s regional network, the collaboration aims to deliver high-quality, affordable biosimilars to patients, reinforcing leadership in the regional biologics market.